media won�t investigate medically-caused death numbers
.
.
.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
"the big unanswered question is concerns over safety in pregnancy," she says. cgrp levels are lower than normal in pregnant women who have
.
.imagine a congressional hearing held before media cameras, with reporters all over the us and europe ready with shocking articles about one of the leading causes of death�
.